| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4026167 | Ophthalmology | 2014 | 13 Pages |
Abstract
Ranibizumab treatment, irrespective of retreatment criteria, provided superior BCVA gains versus vPDT up to month 3. Ranibizumab treatment guided by disease activity criteria was noninferior to VA stabilization criteria up to month 6. Over 12 months, individualized ranibizumab treatment was effective in improving and sustaining BCVA and was generally well tolerated in patients with myopic CNV.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Sebastian MD, PhD, Vilma Jurate MD, PhD, Guna MD, PhD, Ugo MD, Kyoko MD, Tarun MD, Tien Y. MD, PhD, Rufino MD, PhD, Stefan PhD, Margarita MD, RADIANCE Study Group RADIANCE Study Group,